Duvelisib
Sign in to save this workspacePrimary targets: PI3K · FDA status: FDA Approved
Selectivity scorecard
KISS
100.00
Gini
0.716
CATDS
0.030
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Duvelisib. Strongest target: PDK2_PDHK2 at 42.7% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | PDK2_PDHK2 | 42.7% | 57.3% |
| 2 | CAMKK2 | 34.4% | 65.6% |
| 3 | DNA_PK | 33.4% | 66.6% |
| 4 | PKG2_PRKG2 | 33.3% | 66.7% |
| 5 | VRK1 | 24.2% | 75.8% |
| 6 | P38A_MAPK14 | 21.9% | 78.1% |
| 7 | LYN | 21.7% | 78.3% |
| 8 | STK39_STLK3 | 21.6% | 78.4% |
| 9 | PKMYT1 | 20.3% | 79.7% |
| 10 | GSK3A | 18.7% | 81.3% |
| 11 | AURORA_C | 18.6% | 81.4% |
| 12 | HASPIN | 18.5% | 81.5% |
| 13 | CDK2_CYCLIN_A1 | 18.2% | 81.8% |
| 14 | MUSK | 18.2% | 81.8% |
| 15 | MEKK3 | 17.6% | 82.4% |
| 16 | ITK | 17.5% | 82.5% |
| 17 | ROS_ROS1 | 16.5% | 83.5% |
| 18 | EPHA4 | 15.8% | 84.2% |
| 19 | PKCTHETA | 15.4% | 84.6% |
| 20 | PDK1_PDPK1 | 15.2% | 84.8% |
Selectivity landscape
Where Duvelisib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Duvelisib.
Annotations
Sign in to read and post annotations.
Loading…